65.11 +0.00 (0.00%)
JNJ
Stock Details
Last Trade:65.11 Change:+0.00 (0.00%) Prev Close:65.11 Open: 65.25 Days Range:64.81 – 65.49 52 Week Range: 49.49 - 65.95 Volume:1180 P/E: 14.80EPS:4.40
View AllRecent Alerts 03/22/10
Recent Alert on 03/16/10 at 12:59pm
Study Shows Record $65 billion Spent by U.S. Biopharmaceutical Companies in R&D
Study Shows Record $65 billion Spent by U.S. Biopharmaceutical Companies in R&D
Burrill & Company reports a record $65.3 billion has been spent by U.S. Biopharmaceutical Companies on Research & Development (R&D) in 2009. The firm said spending is up approximately $1.5 billion over 2008. Some firms to note Amgen, Inc.... Read More
Recent Alert on 03/16/10 at 12:59pm
Study Shows Record $65 billion Spent by U.S. Biopharmaceutical Companies in R&D
Study Shows Record $65 billion Spent by U.S. Biopharmaceutical Companies in R&D
Recent Alert on 03/16/10 at 10:37am
UBS Maintains a 'Buy' Rating on Boston Scientific (BSX); Adjusts Estimates & PT
UBS Maintains a 'Buy' Rating on Boston Scientific (BSX); Adjusts Estimates & PT
Recent Alert on 02/17/10 at 11:13am
Merriman Curhan Ford Maintains a 'Buy' on Cyclacel Pharmaceuticals (CYCC); Raises PT Range
Merriman Curhan Ford Maintains a 'Buy' on Cyclacel Pharmaceuticals (CYCC); Raises PT Range
Recent Alert on 02/16/10 at 5:23pm
Buffett's Berkshire Hathaway Ups Stakes In RSG and WFC, Lowers Stakes In PG and JNJ, Among Others Moves
Buffett's Berkshire Hathaway Ups Stakes In RSG and WFC, Lowers Stakes In PG and JNJ, Among Others Moves
View AllRecent Press Releases
No Recent Press Releases Available
View AllRecent SEC Filings
No Recent SEC Filings Available
View AllRecent Blog Posts
Blog Posts on 03/18/10 at 3:25am
High Conviction: The Dominant Generic Drugmaker Will Widen Its Lead
High Conviction: The Dominant Generic Drugmaker Will Widen Its Lead